Cargando…

TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer

In treating patients with castration resistant prostate cancer (CRPC), enzalutamide, the second-generation androgen receptor (AR) antagonist, is an accepted standard of care. However, clinical benefits are limited to a median time of 4.8 months because resistance inevitably emerges. To determine the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Geun Taek, Rosenfeld, Jeffrey A., Kim, Won Tae, Kwon, Young Suk, Palapattu, Ganesh, Mehra, Rohit, Kim, Wun-Jae, Kim, Isaac Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752758/ https://www.ncbi.nlm.nih.gov/pubmed/31536510 http://dx.doi.org/10.1371/journal.pone.0213488

Ejemplares similares

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

RNA-seq profile of African American men with a clinically localized prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2021)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
por: Chung, Jae-Seung, et al.
Publicado: (2019)

WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages
por: Lee, Geun Taek, et al.
Publicado: (2018)

TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer
por: Wen, Yu-Ching, et al.
Publicado: (2021)

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
por: Kvorning Ternov, Klara, et al.
Publicado: (2019)

MicroRNAs in prostate cancer
por: Kim, Won Tae, et al.
Publicado: (2012)

Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer
por: Kang, Ho Won, et al.
Publicado: (2013)

Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes
por: Ning, Shu, et al.
Publicado: (2022)

Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels
por: Kim, Won Tae, et al.
Publicado: (2011)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects
por: Kim, Won Tae, et al.
Publicado: (2019)

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
por: Luo, Jie, et al.
Publicado: (2019)

Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis
por: Liu, Bo, et al.
Publicado: (2021)

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
por: Choi, Jae Duck, et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
por: Lopes, Nair, et al.
Publicado: (2021)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2020)

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
por: Benoist, Guillemette E., et al.
Publicado: (2020)

Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
por: Greene, John, et al.
Publicado: (2019)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
por: Toren, Paul, et al.
Publicado: (2016)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma
por: Ha, Yun-Sok, et al.
Publicado: (2014)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
por: McCutcheon, Stephanie B.
Publicado: (2013)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer
por: Wang, Lili, et al.
Publicado: (2021)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
por: Jung, Seung Il, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pnvb8qd37vq55hn1siivabofas